Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY34.06 CNY
Change Today +0.90 / 2.71%
Volume 1.1M
As of 9:37 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

tianjin chase sun pharm-a (300026) Snapshot

Open
CNY33.50
Previous Close
CNY33.16
Day High
CNY34.14
Day Low
CNY33.50
52 Week High
03/25/15 - CNY34.45
52 Week Low
04/2/14 - CNY22.07
Market Cap
20.7B
Average Volume 10 Days
11.4M
EPS TTM
CNY0.87
Shares Outstanding
607.7M
EX-Date
--
P/E TM
39.3x
Dividend
CNY0.10
Dividend Yield
0.20%
Current Stock Chart for TIANJIN CHASE SUN PHARM-A (300026)

Related News

No related news articles were found.

tianjin chase sun pharm-a (300026) Related Businessweek News

No Related Businessweek News Found

tianjin chase sun pharm-a (300026) Details

Tianjin Chase Sun Pharmaceutical Co., Ltd is engaged in the research, development, manufacture, and distribution of various pharmaceutical products in China. The company offers XUEBIJING injection for the treatment of sepsis; TCM products; chemical synthetic drugs; biotechnology drugs; and medical devices. It is also involved in the research and development of various drugs in the therapeutic areas of pulmonary hypertension, leukemia, cardiovascular and cerebrovascular disease, arthritis, vascular disease, Ischemic stroke, HCV, psychosis, and chemotherapy, as well as anaesthesia drugs and Immunomodulator. Tianjin Chase Sun Pharmaceutical Co., Ltd was founded in 1996 and is based in Tianjin, China.

tianjin chase sun pharm-a (300026) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

tianjin chase sun pharm-a (300026) Key Developments

Tianjin Chase Sun Pharmaceutical Proposes Final Dividend for 2014

Tianjin Chase Sun Pharmaceutical Co., Ltd. announced the final distribution proposal for 2014. The company announced a cash dividend of CNY 1.00000000 per 10 shares (tax included).

Tianjin Chase Sun Pharmaceutical Co., Ltd. to Report Fiscal Year 2014 Results on Mar 31, 2015

Tianjin Chase Sun Pharmaceutical Co., Ltd. announced that they will report fiscal year 2014 results on Mar 31, 2015

Tianjin Chase Sun Pharmaceutical Approves Amendments to Articles of Association

Tianjin Chase Sun Pharmaceutical held first extraordinary general meeting of 2015 on 15 January 2015. During the meeting, shareholders of the company approved amendments to the company's articles of association.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300026:CH CNY34.06 CNY +0.90

300026 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300026.
View Industry Companies
 

Industry Analysis

300026

Industry Average

Valuation 300026 Industry Range
Price/Earnings 42.6x
Price/Sales 6.8x
Price/Book 8.6x
Price/Cash Flow 45.1x
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIANJIN CHASE SUN PHARM-A, please visit www.chasesun.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.